“…A noteworthy article published by the University of Recife Bio-equivalence centre, in May 2002, in the Anais da Academia Brasileira de Ciências (Annals of the Brazilian Academy of Sciences), traced bio-equivalence testing on similar drugs in Brazil back to 1995: "our research group started clinical trials and bioequivalence studies, with the collaboration of the public pharmaceutical laboratory of Pernambuco State (LAFEPE), the Brazilian official company to pioneer the development of medicines for AIDS and herpes virus treatment, between 1995 and 1998, even before the establishment of generic policy in Brazil" 31 . The article then gave the results of bio-equivalence for AZT, Ganiclovir, didanosine, lamivudine and zalcitabine, and for a LAFEPE fixed-dose combination "similar to the reference medicine".…”